

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.weylo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/597,034	10/03/2006	Fraser W. Scott	034205.003 (08899427US1)	5076
ospharops SUZANNAH K. SUNDBY SMITH, GAMBRELL & RUSSEL, LLP 1130 Connecticut Avenue, NW Suite 1130 WASHINGTON, DC 20036			EXAMINER	
			EWOLDT, GERALD R	
			ART UNIT	PAPER NUMBER
			1644	
			NOTIFICATION DATE	DELIVERY MODE
			08/04/2009	ELECTRONIC

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

SSUNDBY@SGRLAW.COM dcdocketing@sgrlaw.com



## UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450

	APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.	
	10507034	10/3/06	SCOTT ET AI	034205 003	

(08899427US1)

Suite 1130 WASHINGTON DC 20036 COTT ET AL.

EXAMINER

SUZANNAH K, SUNDBY
SMITH, GAMBRELL & RUSSEL, LLP
130 Connecticut Avenue. NW

 ART UNIT
 PAPER

 1644
 709

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

## Commissioner for Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set foorth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Specifically, all amino acid sequences in the claims must be identified by SEQ ID NOs. Where SEQ ID NOs: have been added to the specification the specification must reflect said addition by underlining. Finally, the Sequence Listing must include the Inventors' names.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.816(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

/G.R. Ewoldt/ Primary Examiner, Art Unit 1644